Agency notice: FDA says BROMFED-DM was not withdrawn for safety or effectiveness
Federal · applicability depends on the document
The FDA has determined that BROMFED-DM syrup was not withdrawn from sale for reasons of safety or effectiveness.
The agency says it will not begin procedures to withdraw approval of abbreviated new drug applications referring to the product and may continue approving them if they meet relevant legal and regulatory requirements.
Based on the linked record from Federal Register ↗. Our reporting and verification standards.
Source, dates and supporting record
- Source published
- Nov 18, 2026
- Last checked
- Nov 19, 2026, 2:45 PM EST
- Record status
- Agency notice
Supporting excerpts
The Food and Drug Administration (FDA, Agency, or we) has determined that BROMFED-DM (brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride) syrup, 2 milligrams (mg)/5 milliliters (mL); 10 mg/5 mL; 30 mg/5 mL, was not withdrawn from sale for reasons of safety or effectiveness.
This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
Original source text
Source wording and its time zone may differ. Date-only dates are preserved. Timestamps here use Eastern Time. Evidence version: 74d8ae4c842438ff7f321b570d9b3d63e5200e459922624ff22d8de22bcf21c2
Source guidance
Original guidance from the issuing source. For current warnings and instructions, consult that source directly. This site is not an emergency notification service.
